CIPLA FINANCIAL RESULTS: Drugs manufacturer reports Ugx 26.5bn revenue decline

Cipla, the manufacturer of Anti Retro Viral drugs says it will not pay its shareholders any dividend, given that its sales revenue dropped by 8.9% a whopping 26.5 Billion shillings in value. With Cipla’s operational costs up by 26.7% hitting 34.1 Billion shillings, officials say that this will going forward be off set by a new 18.5 Billion in sales from the Global Fund. Cipla, has been anchoring its growth revenues from Government orders for ARVs drugs, with over 15 countries across Africa, but which has not been forthcoming


Subscribe to Our Channel
For more news visit
Follow us on Twitter
Like our Facebook page

Leave a Comment